My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

34.66 +0.20 (+0.58%)
Streaming Delayed Price Updated: 10:38 AM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores. 
Via Benzinga
Analyst Expectations For Dianthus Therapeutics's Future
 
Via Benzinga
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline
Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results. 
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
 
Via Benzinga
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
 
Via Benzinga
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
 
Via Benzinga
Top movers in Monday's pre-market session
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026. 
Via Chartmill
Dianthus (DNTH) Q2 Loss Widens 80%
Via The Motley Fool
Expert Ratings For Dianthus Therapeutics
 
Via Benzinga
Navigating 4 Analyst Ratings For Dianthus Therapeutics
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
 
Via Benzinga
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
 
Via Benzinga
Friday's pre-market session: top gainers and losers
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
 
Via Benzinga
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
 
Via Benzinga
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement. 
Via Benzinga
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. 
Via Benzinga
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023
Dianthus Therapeutics just reported results for the third quarter of 2023. 
Via InvestorPlace
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.